Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Gains from Investment Securities (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Gains from Investment Securities for 13 consecutive years, with $2.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities rose 53.23% to $2.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.0 million, a 286.65% increase, with the full-year FY2024 number at $1.9 million, down 24.12% from a year prior.
  • Gains from Investment Securities was $2.1 million for Q3 2025 at Theravance Biopharma, up from $2.0 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $5.6 million in Q1 2021 to a low of -$2.6 million in Q2 2023.
  • A 5-year average of $1.0 million and a median of $1.1 million in 2024 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: tumbled 2050.0% in 2023, then skyrocketed 8030.61% in 2024.
  • Theravance Biopharma's Gains from Investment Securities stood at $5.6 million in 2021, then crashed by 143.79% to -$2.4 million in 2022, then decreased by 7.1% to -$2.6 million in 2023, then skyrocketed by 200.91% to $2.6 million in 2024, then decreased by 21.04% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Gains from Investment Securities are $2.1 million (Q3 2025), $2.0 million (Q2 2025), and $874000.0 (Q1 2025).